ProductsBack/InVivoMAb anti-Zika virus E protein DIII-LR

InVivoMAb anti-Zika virus E protein DIII-LR

Name: InVivoMAb anti-Zika virus E protein DIII-LR
SKU: BE0431_B56
Availability: BackOrder

BE0431

ApplicationsFlow Cytometry, Western Blot, ELISA, Neutralisation/Blocking, Other Application

Product group Antibodies

ReactivityVirus

Overview

Supplier
Bio X Cell
Product Name
InVivoMAb anti-Zika virus E protein DIII-LR
Delivery Days Customer
7
Applications
Flow Cytometry, Western Blot, ELISA, Neutralisation/Blocking, Other Application
Certification
Research Use Only
Clonality
Monoclonal
Clone ID
ZV-67
Concentration
4-11 mg/ml
Estimated Purity
≥95% , Determined by SDS-PAGE
Host
Mouse
Isotype
IgG2c
Reactivity
Virus
Storage Instruction
2°C to 8°C
UNSPSC
41116161

The effect of single mutations in Zika virus envelope on escape from broadly neutralizing antibodies.
Read this paper
An optimized messenger RNA vaccine candidate protects non-human primates from Zika virus infection.
Read this paper
Zika virus spreads through infection of lymph node-resident macrophages.
Read this paper
Resurfaced ZIKV EDIII nanoparticle immunogens elicit neutralizing and protective responses in vivo.
Read this paper
Neutralization of Zika virus by E protein domain III-Specific human monoclonal antibody.
Read this paper
Distinct neutralizing antibody correlates of protection among related Zika virus vaccines identify a role for antibody quality.
Read this paper
Mechanism of differential Zika and dengue virus neutralization by a public antibody lineage targeting the DIII lateral ridge.
Read this paper
Identification of Novel Natural Products as Effective and Broad-Spectrum Anti-Zika Virus Inhibitors.
Read this paper
Determinants of Zika virus host tropism uncovered by deep mutational scanning.
Read this paper
Exosomes mediate Zika virus transmission through SMPD3 neutral Sphingomyelinase in cortical neurons.
Read this paper